H1 profitability beat; but needs internal biosimilars for sustained re-rating
21/08/26 -"The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though profitability was underpinned by improvements in ..."
Pages
57
Language
English
Published on
21/08/26
You may also be interested by these reports :
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...
21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...
21/08/26
Moderna’s mRNA cancer vaccine combined with Merck’s Keytruda does look like a game changer for the wider pharma industry. It looks like a decisive ...
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...